← Back to Clinical Trials
Recruiting NCT05902910

NCT05902910 Efficacy and Acceptability of the Luna EMG Rehabilitation Robot on Motor Recovery of the Upper Limb in the Chronic Phase of Stroke

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05902910
Status Recruiting
Phase
Sponsor University Hospital, Brest
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 5 participants
Start Date 2023-06-12
Primary Completion 2026-06-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
LUNA-EMG Robot

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 5 participants in total. It began in 2023-06-12 with a primary completion date of 2026-06-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Recent work on large cohorts of chronic stroke (\>6 months post-stroke) have shown that intensive training of the upper limb in the chronic stroke patients can lead to substantial motor and functional gains that are maintained at 6 months post intervention. A very prolonged (12 weeks) and very intensive (5 hours daily) training applied to chronic patients after stroke brings a substantial gain both motor and functional which is maintained at 3 months post intervention. Robotic rehabilitation have been shown to be as effective as any other treatment used in rehabilitation. But the methods of implementation remain widely debated. At that time, most robotic therapies have tried to reproduce functional movement mainly pointing objects. We want to demonstrate that analytic movements of the elbow and the shoulder performed with the Luna-EMG robot can replace part of usual physiotherapy treatment with at least the same effectiveness on the recovery of fluid movements of the upper limb after a stroke.

Eligibility Criteria

Inclusion Criteria: * Age \>= 18 years * Hemiparesis after a first stroke with more than 1 year time interval * Functional upper limb: ability to do a pointing task at 90% of the hand-acromion distance (free trunk). * Spastic hypertonia of the elbow flexors 0-2/4 on the Modified Ashworth scale * Patient affiliated with social security * Patient having signed a consent to participate in the research Exclusion Criteria: * Inability to sign written consent * Flexed elbow \> 30° during passive mobilization of the upper limb * EVA\>3 in the upper limb at rest or during mobilization * Complete loss of upper limb proprioception * Neuro-orthopedic surgery of the upper limb for spasticity: neurotomy, tenotomy, transfer * Pregnant or breastfeeding woman

Contact & Investigator

Central Contact

Olivier Remy-Neris, PU-PH

✉ olivier.remyneris@chu-brest.fr

📞 +33 2 98 22 31 52

Principal Investigator

Olivier Remy-Neris, PU-PH

PRINCIPAL INVESTIGATOR

CHRU BREST

Frequently Asked Questions

Who can join the NCT05902910 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05902910 currently recruiting?

Yes, NCT05902910 is actively recruiting participants. Contact the research team at olivier.remyneris@chu-brest.fr for enrollment information.

Where is the NCT05902910 trial being conducted?

This trial is being conducted at Brest, France.

Who is sponsoring the NCT05902910 clinical trial?

NCT05902910 is sponsored by University Hospital, Brest. The principal investigator is Olivier Remy-Neris, PU-PH at CHRU BREST. The trial plans to enroll 5 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology